RxDoctor Payments DataLook up a doctor →

Robert Salazar, MD

Cardiovascular Disease · Kingwood, TXNPI 1891014114

Payments from drug & device makers

$571,837in general payments, 2019–2025

Across 951 payments — averaging $601.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$274K
  • Penumbra, Inc.$172K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$93K
  • Saranas, Inc.$11K
  • Abbott$5K
  • Medtronic$3K
  • plus $14K from 42 others
$366in research payments, 2019–2025

Across 2 payments — averaging $183.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ZOLL Circulation Inc$220
  • Abiomed$146

What the payments were for

  • Consulting fees$24,5005%
  • Speaking & faculty fees$335,55470%
  • Travel & lodging$82,09217%
  • Food & beverage$36,1108%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$571,837 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$1,218,182
Medicare patients
387
Services billed
8,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide153$221,231
EliquisApixaban164$190,050
EntrestoSacubitril/Valsartan131$184,801
MounjaroTirzepatide117$152,275
XareltoRivaroxaban86$101,229
FarxigaDapagliflozin Propanediol71$80,418
JardianceEmpagliflozin22$27,418
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,488
BrilintaTicagrelor17$14,547
Bumetanide203$10,160
Repatha SyringeEvolocumab11$9,465
Metoprolol Succinate297$6,029
Chlorthalidone184$4,901
Midodrine Hcl30$4,409
Ranolazine ErRanolazine32$4,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$539$221,231153 claims
PfizerEliquis$52$190,050164 claims
NovartisEntresto$1,853$184,801131 claims
Lilly USA, LLCMounjaro$45$152,275117 claims
Johnson & JohnsonXarelto$329$101,22986 claims
AstraZenecaFarxiga, Brilinta$59$94,96588 claims
Boehringer IngelheimJardiance$456$27,41822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →